Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 3/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28756691 | 0.88 | MAP3K5 (0.40) | MAP3K5KDM4EALDH1A1SMN1; SMN2ASPH | |
| SCHEMBL12348927 | 0.84 | MAP3K5 (0.43) | MAP3K5 | |
| SCHEMBL2296534 | 0.84 | MAP3K5 (0.51) | MAP3K5KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2300491 | 0.83 | MAP3K5 (0.48) | MAP3K5KDM4EALDH1A1ASPHKDM8 | |
| SCHEMBL14151686 | 0.81 | MAP3K5 (0.51) | MAP3K5KDM4EALDH1A1SMN1; SMN2ASPH | |
| SCHEMBL2304004 | 0.73 | MAP3K5 (0.43) | MAP3K5KMT2A | |
| SCHEMBL26581655 | 0.73 | MAP3K5 (0.40) | MAP3K5KDM4EALDH1A1ASPHKDM8 | |
| SCHEMBL20604936 | 0.72 | GABRA1 (0.46) | MAP3K5KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL19475816 | 0.71 | MAP3K5 (0.44) | MAP3K5KDM4EALDH1A1KDM4C | |
| SCHEMBL25220625 | 0.70 | MAP3K5 (0.43) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| US-9403819-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403819-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20140329850-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA CALIFORNIA, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140329850-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA CALIFORNIA, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8802695-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-12 | — | — | US | disclosed |
| US-8802695-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-12 | — | — | US | disclosed |
| EP-2531501-B1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-20 | — | — | EP | disclosed |
| US-20120316194-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
| EP-2531501-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097079-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329850-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | MAP3K5 8/4885KDM4E 2251/4885ALDH1A1 2965/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | MAP3K5 1914/4885KDM4E 1156/4885ALDH1A1 2556/4885 |
| US-20120316194-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | MAP3K5 8/4885KDM4E 2251/4885ALDH1A1 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.